Potential of Human Wharton’s Jelly Mesenchymal Stem Cells (hWJMSCs) Secretome for COVID-19 Adjuvant Therapy Candidate

Widowati, Wahyu and Wargasetia, Teresa Liliana and Rahardja, Fanny and Gunanegara, Rimonta F. and Handayani, Tri and Kusuma, Hanna Sari W. and Arunwardana, Seila and Wijayanti, Cahyaning Riski and Rizal, Rizal (2021) Potential of Human Wharton’s Jelly Mesenchymal Stem Cells (hWJMSCs) Secretome for COVID-19 Adjuvant Therapy Candidate. In: 2021 IEEE International Conference on Health, Instrumentation & Measurement, and Natural Sciences (InHeNce), 14-16 July 2021, Medan.

[img]
Preview
Text
1.9 B10. IEEE 22, Potential of human whartons jelly + detail.pdf

Download (4Mb) | Preview
[img]
Preview
Text
1.9 Turnitin, B10. IEEE 22, Potential of human whartons jelly.pdf

Download (1694Kb) | Preview

Abstract

SARS-CoV-2 is a virus that causes a serious lifethreatening disease known as COVID-19. Patients with COVID‑19 can develop acute respiratory distress syndrome (ARDS) and multiorgan failure requiring safe and effective therapy. The human Wharton’s Jelly Mesenchymal Stem Cells (hWJMSCs) can act as an anti-inflammatory and regenerative properties due to their secretion such as cytokine, growth factor, antimicrobial, and chemokine. A natural way of producing the secreted proteins of a cell (secretome) is by culturing mesenchymal stem cells (MSCs) under starvation or serum deprivation condition. This research was performed to measure the level of Fibroblast Growth Factor-7 (FGF-7), antibacterial protein LL-37 (LL-37), interleukin 1 Receptor Antagonist (IL-1ra), respectively, in the secretome of hWJMSCs. The secretome levels at: non-starvation, 24-, 48-, and 72-hours starvation periods were measured using ELISA method. The hWJMSCs secreted levels of FGF-7, LL-37, and IL-1ra were 46.74 – 72.13 pg/mL, 1.70 – 4.14 ng/mL, 1.35 – 8.32 pg/mL, respectively. The longer the starvation period of cells, the higher the protein levels produced. The hWJMSCs secrete FGF-7, LL-37, IL-1ra, longer starvation periods of cells will increase secretome levels. The hWJMSCs could potentially serve as adjuvant therapy for COVID-19.

Item Type: Conference or Workshop Item (Paper)
Uncontrolled Keywords: hWJMSCs, Acute Respiratory Distress Syndrome, cytokine storm, SARS-CoV-2
Subjects: R Medicine > R Medicine (General)
Depositing User: Perpustakaan Maranatha
Date Deposited: 19 Mar 2022 11:11
Last Modified: 04 Feb 2023 04:22
URI: http://repository.maranatha.edu/id/eprint/30158

Actions (login required)

View Item View Item